|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8604 USD | -4.93% |
|
-3.78% | -33.30% |
| Apr. 25 | Transcript : OptiNose, Inc. - Special Call | |
| Apr. 25 | OptiNose, Inc. Provides Earnings Guidance for the Full Year 2025 | CI |
OptiNose, Inc. revised revenue guidance for the full year of 2023. The Company expects XHANCE net revenues for the full year of 2023 to be between $66.0 to $70.0 million. Previously, the Company expected XHANCE net revenues for the full year of 2023 to be between $64.0 to $70.0 million.
In addition, the Company continues to expect the full year 2023 XHANCE average net revenue per prescription to be approximately $200.
| 1st Jan change | Capi. | |
|---|---|---|
| -33.30% | 97.26M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
OPTINOSE, INC. 
